Given that the interaction of menin and KMT2A protein is essential in initiating the oncogenesis of HOXA9-driven leukemia, menin-KMT2A inhibitors are promising molecular-targeting agents applicable to a considerable proportion of AML patients. This evidence concerns the gene KMT2A and acute myeloid leukemia.